Wed, Sep 17, 2014, 7:36 AM EDT - U.S. Markets open in 1 hr 54 mins

Recent

% | $
Quotes you view appear here for quick access.

Abbott Laboratories Message Board

  • bluecheese4u bluecheese4u Jan 23, 2013 8:39 AM Flag

    Abbott Reports Fourth-Quarter and Full-Year 2012 Results

    Abbott Reports Fourth-Quarter and Full-Year 2012 Results

    Fourth-Quarter Ongoing EPS of $1.51 (GAAP EPS of $0.66)
    Full-Year Ongoing EPS of $5.07 (GAAP EPS of $3.72)
    Completed Launch of AbbVie, a New Biopharmaceutical Company
    Company Issues Strong Earnings Outlook for 2013
    Date: January 23, 2013

    Abbott Park, Illinois (NYSE: ABT) — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2012.

    Fourth-quarter diluted earnings per share, excluding specified items, were $1.51. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.66, including specified items.
    Full-year diluted earnings per share, excluding specified items, were $5.07, exceeding Abbott’s initial guidance range. Diluted earnings per share under GAAP were $3.72, including specified items.
    Excluding foreign exchange, worldwide sales increased 5.6 percent. Reported sales increased 4.4 percent, including an unfavorable 1.2 percent effect of foreign exchange.
    On Jan. 1, 2013, Abbott completed the launch of AbbVie, a new research-based biopharmaceutical company.
    Abbott launched numerous new products across its diversified businesses in 2012, positioning the company well for future growth. Key pipeline innovations include the launch of its Absorb™ bioresorbable vascular scaffold; next-generation drug-eluting stent, XIENCE Xpedition™; 80 launches across its Nutrition business; new tests in Diagnostics; as well as several new product and geographic expansion initiatives in Established Pharmaceuticals, Diabetes Care and Vision Care.
    "In 2012, we achieved a significant milestone in Abbott's 125-year history with the creation of AbbVie while delivering another year of strong results," said Miles D. White, chairman and chief executive officer, Abbott. "Abbott’s mix of diversified healthcare businesses and pipeline is favorably aligned with key healthcare and emerging market trends and well positioned to deliver top-tier growth in 2013."

    abbottDOTcom/press-release/abbott-reports-fourthquarter-and-fullyear-2012-results.htm

 
ABT
42.90+0.18(+0.42%)Sep 16 4:03 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.